Quelling of Excitotoxicity in Acute Stroke With Ketamine

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 120 participants.

Also called NCT03223220

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Lower Merion Neurology Research Foundation (from the registry)
Registry
  • NCT NCT03223220
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT03223220. Randomized; quadruple masking; primary purpose treatment. Start 2024-07-01 (anticipated); primary completion 2026-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Quelling of Excitotoxicity in Acute Stroke With Ketamine
Acronym
QUEST-KETA
Condition
Acute Ischemic Stroke
Intervention (Drug)
Ketamine
Intervention (Other)
Normal Saline
Intervention (Drug)
Midazolam injection
Lead sponsor
Lower Merion Neurology Research Foundation (class: other)

Record details

Record id
cardio:ct-nct03223220
Content hash
9c090758b1aa1d9013fe6a25b2194bec3f212209dd21508be9c2ff44009ed674